Glycopyrronium (PT001) vs Ipratropium
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline
Glycopyrronium (PT001)
Developed by AstraZeneca
NCT03358147 · Phase 2/3 · completed
The study was randomized and quadruple-masked for the placebo comparison, included 1,077 participants, and used placebo and open-label active comparators. Its primary measure was a lung-function surrogate rather than a hard clinical outcome, and although the reported PT001 values were numerically higher than placebo, whether the prespecified primary comparison was statistically significant is not stated.
Next expected readout: May 2029 · NCT07525375 (registry estimate)
Reported efficacy
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412) (unclear)
Result source: NCT03358147
Ipratropium
Marketed by Boehringer Ingelheim
NCT06074185 · Phase 2 · completed
The study was not randomized or blinded and compared patients treated before and after implementation of the bundle rather than using a concurrent controlled trial; the intervention also included dexamethasone and a checklist, so the effect cannot be attributed to ipratropium alone. Although hospital admission is a clinical endpoint, the primary comparison was based on a small and internally inconsistent set of reported participants, with no reported significance analysis, so the result is unclear.
No aligned efficacy figure on record for this race.
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Glycopyrronium (PT001) | Ipratropium |
|---|---|---|
| Severe exacerbations, annualised rate | —Not reported | —Not reported |
| Trough FEV1, change | 0.1 vs 0.1±0 vs placeboNCT033581472 other results
| —Not reported |
| ACQ-5, change | -0.9 vs -0.9+0.1 vs placeboNCT033581472 other results
| —Not reported |
| OCS dose reduction | —Not reported | —Not reported |
Severe exacerbations, annualised rate
- Glycopyrronium (PT001)
- —Not reported
- Ipratropium
- —Not reported
Trough FEV1, change
- Glycopyrronium (PT001)
- 0.1 vs 0.1±0 vs placeboNCT03358147
2 other results
- 0.1 vs 0.1 NCT03358147
- 0.1 vs 0.1 NCT03358147
- Ipratropium
- —Not reported
ACQ-5, change
- Glycopyrronium (PT001)
- -0.9 vs -0.9+0.1 vs placeboNCT03358147
2 other results
- -0.8 vs -0.9 NCT03358147
- -1.0 vs -0.9 NCT03358147
- Ipratropium
- —Not reported
OCS dose reduction
- Glycopyrronium (PT001)
- —Not reported
- Ipratropium
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Glycopyrronium (PT001): 4 of 4 rows · Ipratropium: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Glycopyrronium (PT001) | Ipratropium |
|---|---|---|
| Dropout rate | 14.5%28.8 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results16.3%14.4 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 14.2%7.2 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 | —a NCT06074185 · Phase 2 · combination show 4 more results0% NCT04617015 · Phase 1 · registry result, not featured evidence 0%Arg/Arg Genotype on Advair (Flutic NCT00521222 · Phase na · registry result, not featured evidence 5.6%Gly/Gly Genotype on Advair (Flutic NCT00521222 · Phase na · registry result, not featured evidence 0% NCT00583778 · Phase na · registry result, not featured evidence · combination |
| Discontinued due to AEs | 1.3%28.8 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results3.8%14.4 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 2.9%7.2 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 | —a NCT06074185 · Phase 2 · combination show 4 more results— NCT04617015 · Phase 1 · registry result, not featured evidence —Arg/Arg Genotype on Advair (Flutic NCT00521222 · Phase na · registry result, not featured evidence —Gly/Gly Genotype on Advair (Flutic NCT00521222 · Phase na · registry result, not featured evidence — NCT00583778 · Phase na · registry result, not featured evidence · combination |
| Serious AEs | 3.8%28.8 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results2.9%14.4 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 2.5%7.2 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 | 0%a NCT06074185 · Phase 2 · combination show 4 more results0% NCT04617015 · Phase 1 · registry result, not featured evidence 0%Arg/Arg Genotype on Advair (Flutic NCT00521222 · Phase na · registry result, not featured evidence 0%Gly/Gly Genotype on Advair (Flutic NCT00521222 · Phase na · registry result, not featured evidence 0% NCT00583778 · Phase na · registry result, not featured evidence · combination |
| Most frequent reported AEs | 28.8 μg upper respiratory tract infection 6% (placebo 8%) nasopharyngitis 4.7% (placebo 3.4%) sinusitis 4.3% (placebo 1.3%) NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results14.4 μg nasopharyngitis 6.3% (placebo 3.4%) upper respiratory tract infection 5.8% (placebo 8%) sinusitis 2.9% (placebo 1.3%) NCT03358147 · Phase 2/3 · Asthma · phase 2/3 7.2 μg nasopharyngitis 7.1% (placebo 3.4%) upper respiratory tract infection 5.8% (placebo 8%) sinusitis 1.7% (placebo 1.3%) NCT03358147 · Phase 2/3 · Asthma · phase 2/3 | a upper respiratory infection 13.3% dyspnea 6.7% right foot fracture 6.7% NCT00521222 · Phase na · registry result, not featured evidence show 1 more resultdyspnea 11.8% cough 5.9% pneumonia 5.9% NCT00521222 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Glycopyrronium (PT001)
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
Ipratropium
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glycopyrronium (PT001)'s landscape · Ipratropium's landscape